CLINICAL STUDIES ON AC-1370 IN THE TREATMENT OF RESPIRATORY TRACT INFECTIONS

Abstract

Clinical investigations were performed on AC-1370, a new cephalosporin.
AC-1370 was administered to a total of 13 patients with respiratory tract infections including 10 cases of pneumonia and each one case of pneumonia and pyothorax, acute bronchitis, acute exacerbation of chronic bronchitis.
The drug was administered at a daily dose of 2g for five days in one case, 10 days in one case, 14 days in 10 cases and 17 days in one case.
The drug was discontinued after five days' therapy in one case because of drug fever.
The following four potential pathogens were recovered from the sputum at a start of the treatment with AC-1370, one strain each of β-Streptococcus, P. aeruginosa, S. pneumoniae, H. influenzae. All of them were eradicated during the treatment with AC-1370.
The clinical response to the treatment with AC-1370 was excellent in six cases, good in six cases and fair in one case.
A drug fever was observed in one case of pneumonia.
A slight elevation of serum transaminase was observed in two cases and eosinophilia in one case.
From the above results, it is concluded that AC-1370 is one of effective and useful the third generation cephems against RTIs.